#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA4419323	F	Inhibition of LPS-induced TNFalpha production in PBMC (unknown origin) incubated for 16 hrs by ELISA	Not specified	21		cell-based format	Patent Bioactivity Data
2.	ALA4419324	T	Toxicity in human U937 cells assessed as reduction in cell viability incubated for 16 hrs by trypan blue dye based assay	Homo sapiens	21		cell-based format	Patent Bioactivity Data
3.	ALA4419325	T	Therapeutic index, ratio of LC50 for toxicity in human U937 cells assessed as reduction in cell viability incubated for 16 hrs by trypan blue dye based assay to EC50 for inhibition of LPS-induced TNFalpha production in PBMC (unknown origin) incubated for 16 hrs by ELISA	Homo sapiens	21		cell-based format	Patent Bioactivity Data
4.	ALA4419342	F	Suppression of lung injury in mouse model of Pseudomonas aeruginosa PA103 infection-induced pneumonia assessed as reduction in lavage cell counts at 30 or 150 ug, ip pre-treated before infection	Mus musculus	1		organism-based format	Patent Bioactivity Data
5.	ALA4419343	F	Suppression of lung injury in mouse model of Pseudomonas aeruginosa PA103 infection-induced pneumonia assessed as reduction in lavage protein concentration at 30 or 150 ug, ip pre-treated before infection	Mus musculus	1		organism-based format	Patent Bioactivity Data
6.	ALA4419344	F	Suppression of lung injury in mouse model of Pseudomonas aeruginosa PA103 infection-induced pneumonia assessed as reduction in lavage IL6 levels at 30 or 150 ug, ip pre-treated before infection	Mus musculus	1		organism-based format	Patent Bioactivity Data
7.	ALA4419345	F	Suppression of lung injury in mouse model of Pseudomonas aeruginosa PA103 infection-induced pneumonia assessed as reduction in neutrophil infiltration at 30 or 150 ug, ip pre-treated before infection by May-Grunwald and Geimsa staining based assay	Mus musculus	1		organism-based format	Patent Bioactivity Data
8.	ALA4419346	F	Suppression of lung injury in mouse model of Pseudomonas aeruginosa PA103 infection-induced pneumonia assessed as reduction in cell infiltration at 30 or 150 ug, ip pre-treated before infection by H and E staining based assay	Mus musculus	1		organism-based format	Patent Bioactivity Data
9.	ALA4419347	F	Suppression of smoke-induced chronic lung inflammation in mouse assessed as reduction in lavage cell counts at 100 ug, ip administered as single dose injected after 5 weeks cigarette smoke exposure	Mus musculus	1		organism-based format	Patent Bioactivity Data
10.	ALA4419348	F	Suppression of smoke-induced chronic lung inflammation in mouse assessed as reduction in lavage protein concentration at 100 ug, ip administered as single dose injected after 5 weeks cigarette smoke exposure	Mus musculus	1		organism-based format	Patent Bioactivity Data
11.	ALA4419349	F	Suppression of smoke-induced chronic lung inflammation in mouse assessed as reduction in lavage IL12 levels at 100 ug, ip administered as single dose injected after 5 weeks cigarette smoke exposure	Mus musculus	1		organism-based format	Patent Bioactivity Data
12.	ALA4419350	F	Suppression of IMQ-induced psoriasis in BALB/c mouse model of skin inflammation assessed as reduction in spleen weight at 1 or 5 mg/kg applied topically on daily basis	Mus musculus	1		organism-based format	Patent Bioactivity Data
13.	ALA4419351	F	Suppression of IMQ-induced psoriasis in BALB/c mouse model of skin inflammation assessed as reduction in ear thickness at 1 or 5 mg/kg applied topically on daily basis	Mus musculus	1		organism-based format	Patent Bioactivity Data
14.	ALA4419352	F	Suppression of IMQ-induced psoriasis in BALB/c mouse model of skin inflammation assessed as reduction in psoriasis index at 1 or 5 mg/kg applied topically on daily basis	Mus musculus	1		organism-based format	Patent Bioactivity Data
15.	ALA4419353	F	Suppression of IMQ-induced psoriasis in BALB/c mouse model of skin inflammation assessed as effect on gross appearance at 1 or 5 mg/kg applied topically on daily basis	Mus musculus	1		organism-based format	Patent Bioactivity Data
16.	ALA4419354	F	Suppression of IMQ-induced psoriasis in BALB/c mouse model of skin inflammation assessed as reduction in spleen weight at 1 or 5 mg/kg dosed via drinking water on daily basis	Mus musculus	1		organism-based format	Patent Bioactivity Data
17.	ALA4419355	F	Suppression of IMQ-induced psoriasis in BALB/c mouse model of skin inflammation assessed as reduction in ear thickness at 1 or 5 mg/kg dosed via drinking water on daily basis	Mus musculus	1		organism-based format	Patent Bioactivity Data
18.	ALA4419356	F	Suppression of IMQ-induced psoriasis in BALB/c mouse model of skin inflammation assessed as reduction in psoriasis index at 1 or 5 mg/kg dosed via drinking water on daily basis	Mus musculus	1		organism-based format	Patent Bioactivity Data
19.	ALA4419357	F	Suppression of IMQ-induced psoriasis in BALB/c mouse model of skin inflammation assessed as effect on gross appearance at 1 or 5 mg/kg dosed via drinking water on daily basis	Mus musculus	1		organism-based format	Patent Bioactivity Data
20.	ALA4419358	F	Suppression of dexamethasone-induced muscle atrophy in C57BL mouse assessed as reduction in TRAF6 protein in TA muscle at 0.5 to 5 mg/kg/day dosed via drinking water by immunoblotting analysis	Mus musculus	1		organism-based format	Patent Bioactivity Data